StockData

Harmony Biosciences vs Xeris Biopharma

HRMY and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HRMY and XERS compare

Xeris Biopharma is the larger company, worth 1.6 times as much as Harmony Biosciences ($3.1B against $1.9B).

Xeris Biopharma grew revenue faster over the last twelve months (36.3% versus 24.3% for Harmony Biosciences).

Harmony Biosciences keeps more of each dollar of sales as profit, with a net margin of 18.9% compared with −5.1% at Xeris Biopharma.

Harmony Biosciences scores higher on the StockData Score (18 against 10 for Xeris Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHRMYXERS
Size and price
Market cap$1.9B$3.1B
Share price$33.01$16.80
Change, 1 year−3.0%134%
Change, 5 years−12.1%674%
Beta (5Y)1.110.27
Employees293435
StockData Score
Total score18 (better)10
Valuation score6 (better)0
Growth score24 (better)
Performance score4 (better)3
Health score6 (better)3
Dividend score00
Valuation
P/E10.7×–
P/S2.0× (better)9.1×
P/B1.9×–
EV/EBITDA6.1× (better)84.2×
Fair value$53.99–
Margin of safety38.9%–
Growth
Revenue growth (TTM)24.3%36.3% (better)
Revenue growth, 5Y average40.3%70.2% (better)
Net income growth (TTM)0.20%–
EPS growth (TTM)−0.32%–
Profitability
Gross margin75.4%86.6% (better)
Operating margin24.0% (better)10.9%
Net margin18.9% (better)−5.1%
Return on equity20.5%–
Return on invested capital40.1% (better)22.1%
Financial health
Debt / equity0.15–
Net debt / EBITDA−2.233.45 (better)
Interest coverage17.1× (better)1.3×
Current ratio3.48 (better)1.45
Altman Z-score5.12 (better)3.33
Piotroski F-score58 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions93.0%59.4%
Held by insiders12.1%5.2%
Insider net buying, 12 months−$5.8M−$5.8M (better)
Short interest, % of float13.0%5.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.